Less than two weeks after making a presentation at the SeeThruEquity Conference in Miami Beach, SeeThruEquity increased its price target for ChineseInvestors.com (OTCQB: CIIX) to $3.75.
Less than two weeks after making a presentation at the SeeThruEquity Conference in Miami Beach, SeeThruEquity increased its price target for ChineseInvestors.com (OTCQB: CIIX) to $3.75.
Invictus MD (CSE:IMH, OTC:IVITF) reports that Future Harvest Development Ltd. (of which Invictus MD currently owns 82.5%) has generated $1.578 million in revenue.
Invictus MD Strategies Inc. (CSE:IMH,OTC:IVITF) has a flurry of recent developments as the company builds a portfolio of Canadian licensed producers preparing to move into the recreational market.
Organigram (TSX.V:OGI, OTCQB:OGRMF) began a voluntary recall of a total of 74 products produced between February 1 and December 16, 2016. These lots tested positive for two pesticides that aren't authorized for use on cannabis plants under the Pest Control Products Act but there are long-term benefits for the recall.
The Canadian Bioceutical Corporation (CSE:BCC,OTC:CBICF) announces that it has entered into a Market Making Services Agreement with Venture Liquidity Providers Inc. for an initial 12 month term.
AusCann recently went public via a reverse takeover on the ASX. Their joint-venture with Daya Foundation in Chile and Canopy Growth in Canada puts them at the head of the pack in the Australian market. Canopy Growth Corporation will potentially make the move to buy AusCann.
CBD is one of over 85 cannabinoids present in the cannabis plant, and, unlike THC, it interacts with our naturally occurring systems without being psychotropic, which means it doesn’t make a person “high”.
When heated, myclobutanil is known to create hydrogen cyanide which is extremely poisonous. 3 of the 38 federally licensed marijuana growing companies have had to recall their products due to the presence of the myclobutanil pesticide.
It's a race to riches that has just begun among a handful of Canada’s licensed, industrial-scale medical marijuana growers – each of whom wants to capitalize on in-house IP that can turn cannabis into mainstream medicine. In the quest to find the next GW, Dundee Capital Markets is championing Emerald Heath Therapeutics Inc.
Colorado is on the brink of becoming the first state with licensed pot clubs. But the details of how these clubs will operate are as hazy as the underground clubs operating already.
Shareholders of Medical Marijuana Inc. ($MJNA , a company traded over-the-counter, have had a stellar year. So far, shares are up over 300% since February of last year. So why is this company such a high risk for new Investors?
Courtagen Life Sciences, Inc., has launched Avantra Genetics. Avantra is dedicated to providing advanced genomic information for functional medicine practices. Patients suffering from functional disorders may experience symptoms such as pain, fatigue, numbness or sensations and gastrointestinal distress that can be severe, chronic or debilitating.
Aurora Cannabis Inc. (TSXV:ACB) is a high-flying Canadian medical marijuana producer that is slowly creeping up on Canopy Growth Corp. (TSX:WEED) and Aphria Inc. (TSXV:APH). The company has a $787 million market cap, but it could soon break the $1 billion mark later this year.
Tetra Bio-Pharma (CSE: TBP) (CSE: TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that Health Canada has approved its Phase I clinical study of smoked cannabis.
While the medicinal cannabis industry continues to rapidly advance and expand operations by identifying new leading edge products, leaders are turning towards the expertise and knowledge of other medical sectors, especially with influence from the biopharma sector.